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ABSTRACT 
The Major histocompatibility complex class I (MHC-I) has been characterized in such 
great depth that a number of its key properties are well understood and part of its 
behavior can even be predicted. It is therefore intriguing that the impact of small epitope 
modifications on immunogenicity and the elicitation of T-cell repertoires remain often 
unpredictable and full of surprises.  
 
Substitution of the secondary anchor residue at peptide position 3 from a serine to a 
proline (p3P) significantly increased the stabilization capacity and immunogenicity of the 
melanoma-associated H-2Db (Db)-restricted epitope gp100 (EGS). Despite this strong 
enhancement the conformation of the modified epitope (EGP) was not altered and 
vaccination with EGP generated T-cell responses that recognized cells expressing EGS 
with high functional avidity. Based on these promising results, the p3P modification was 
applied to the highly immunodominant Lymphocytic Choriomeningitis Virus epitope gp33 and 
the associated escape variants Y4F and Y4A. As for gp100, p3P was found to increase the 
MHC stabilization capacity and immunogenicity of the modified epitopes V3P, PA and 
PF, while not altering their structures. Accordingly, T-cell responses were cross-reactive 
between native and p3P enhanced epitopes and, when used for vaccination of C57BL/6 
mice, PF elicited a focused T-cell response against Db/Y4F. 
 
In parallel, surface plasmon resonance (SPR) measurements revealed that p3P did not 
only enhance MHC stabilization capacity but also directly increased the affinity of the 
cognate T-cell receptors (TCRs). To fully characterize the molecular details underlying 
these two enhancing effects, the thermostability, TCR binding and molecular dynamics 
(MD) of Db/EGP were measured in comparison with Db/EGS. Furthermore, the 
contribution of Y159, a highly conserved tyrosine that is structurally juxtaposed to p3P, 
was assessed using a set of soluble Db-Y159 variants. In conclusion, these measurements 
clearly demonstrated that specific interactions of p3P with the aromatic ring of Y159 are 
responsible for the significantly increased MHC stabilization capacity. Surprisingly, the 
enhanced TCR binding was found to be entirely independent of Y159, suggesting a direct 
contribution of the buried proline residue to TCR binding. These findings underscore the 
potential to enhance MHC-I-restricted epitopes at secondary anchor residues, while 
specifically indicating that proline can directly increase TCR affinity, which could not have 
been anticipated from our current understanding of the factors shaping TCR recognition.  
 
Not entirely different from T-cell elicitation, the induction of broadly neutralizing 
antibodies against the Human Immunodeficiency Virus type 1 (HIV-1) is to date still an elusive 
goal despite extensive characterization of the respective antibody-epitope interactions. 
One of the central challenges is that the virus is highly adapted to immune pressure and 
the most relevant antibody epitopes on the HIV envelope proteins (Env) are the least 
immunogenic. Therefore, a highly heterologous prime-boost vaccination strategy was 
designed in which priming of rabbits with HIV-1 env plasmids was followed by a 
 
 
 
 
recombinant Simian Immunodeficiency Virus (SIV) Env boost. While the SIV Env trimers 
were inherently favorable because of their higher stability, the approach was specifically 
chosen to preferentially boost antibody responses against the few sites that are conserved 
in HIV and SIV Env. The described approach was generally validated and warrants future 
investigations as it lead to the elicitation of potent neutralizing antibodies even though it 
remains to be fully established if the highly heterologous nature of the prime boost 
strategy was solely responsible. 
 
In summary, the studies presented in this thesis provide the structural and functional 
platform for a novel and intriguing MHC-I peptide enhancement. Additionally, 
heterologous immunizations of rabbits offer a promising addition to existing vaccination 
strategies against HIV.  
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1 INTRODUCTION	  
1.1 Some	  fundamental	  principles	  of	  adaptive	  immune	  recognition	  	  
The principle features of our adaptive immune system represent a beautiful solution to an 
incredibly complicated question. This is represented by the need to recognize yet 
unknown antigens in near unimaginable variations while not damaging the host. In an 
intriguing way the immune system meets the challenges through an intrinsic ability to 
‘simply’ react against everything, while being specifically instructed only to avoid self. 
1.1.1 Antigen presentation with an emphasis on MHC-I 
Independently from the division between its adaptive and innate arms, the functions of 
the immune system can also be described as the abilities to recognize antigens and to 
mount effector responses against the associated pathogens. Presentation of antigens to the 
immune system is a crucial part of the actual T-cell recognition and the rules of the latter 
are significantly shaped by the properties of the former. The ‘unit of presentation’ in 
antigen recognition is defined by the class I and II major histocompatibility complexes 
(MHC-I and –II, respectively), which present peptide antigens on the cell surface to T 
cells and natural killer (NK) cells. The ubiquitous MHC-I molecules present intracellularly 
processed peptide antigens on the surface of practically all cells in the body, turning them 
into antigen presenting cells (APCs) [6,7], ultimately allowing T-cells to recognize and 
eliminate cells that harbor intracellular pathogens. In contrast, MHC-II molecules, which 
present mainly extracellular peptide antigens, are restricted to professional APCs (pAPCs) 
including dendritic cells (DCs), B-cells and Macrophages. MHC-II/peptide complexes are 
recognized by CD4+ T helper cells and therefore they play a central role in stimulation of 
full immune responses [8]. A main focus of this thesis is the MHC-I-restricted antigen 
presentation and antigen recognition by CD8+ cytotoxic T-cells (CTLs).  
 
The MHCs owe their original description and name to their key role in determining 
rejection or acceptance of (tumor) transplants [9]. This in turn is based on the high 
polymorphism of the MHC, which provides this unique unit of presentation with the 
capacity to present a very wide range of different peptide antigens in different individuals 
[10,11]. This polymorphism defines that the ‘self’ in adaptive immunity is really the 
individual and not for example the species. While MHC restriction and peptide 
presentation will be discussed in detail below, it should be mentioned already here that a 
defining feature of peptide presentation and of the entire adaptive immune system is that 
the presented peptide antigens are not specifically pathogenic or ‘foreign’ but rather 
constitute a more or less representative sample of intra- and extracellular antigens [12,13]. 
This appears to be a sensible characteristic, given the degree to which viruses rely on the 
host machinery for biosynthesis. Although highly hypothetical, it could also be speculated 
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that this allows for a more efficient reaction against members of the same species 
(alloreactivity) as well as against antigens associated with developing malignancies. 
1.1.2 “Nothing in biology makes sense except in the light of…” Lymphocyte selection 
in T-cell immunity  
Attempting to explain the properties of our T- and B-cell repertoires, one must account 
for their ability to (I) not react against itself (tolerance), (II) recognize a virtually unlimited 
variation of antigens, (III) be able to do so even before their appearance in the host and 
(IV) alloreactivity determined by MHC disparity. Awareness of alloreactivity in 
combination with I and II was an early and principal driving force for basic research into 
the fundamentals of the immune system [9,14-16]. A huge leap forward in a conceptual 
understanding of this system was derived from the theory of clonal selection and the 
formal recognition that III essentially ruled out any form of de novo, antigen-induced 
selection for the ability of the immune system to react to foreign antigens [17,18].  
 
The cellular solution to this is somewhat indirect in that a foreign antigen is not 
recognized on the basis of a specific structural property distinguishing it from ‘self’, but on 
the basis of a higher avidity compared to ‘self’. Antigen recognition is mediated by a vast 
repertoire of B- and T-cells of which each member expresses one variant of an equally 
huge, randomly assembled, diverse and cross-reactive repertoire of B- and T- cell 
receptors (BCR and TCR, respectively) [17-19]. This fixed link between individual B- and 
T-cells and their antigen-specificity is the basis of a central and constitutive positive and 
negative selection in which cells are eliminated or stimulated to survive based on their 
specificity, and which takes place in the thymus and bone marrow during T- and B-cell 
development, respectively.  
 
Positive selection assures that all surviving B- and T-cells display BCRs that are properly 
folded, or TCRs with the capacity to recognize MHC/peptide complexes (pMHCs) 
[20,21]. Tolerance is subsequently acquired through negative selection, which eliminates all 
B- and T-cells that recognize ‘self’ antigens with too high avidity [15,16,18,22]. This two-
step selection results in a repertoire of B- and T-cells with the a priori capacity to recognize 
a virtually unlimited variation of antigens while remaining tolerant to ‘self’. Furthermore, it 
also means that the meaning of ‘self’ could be translated to ‘whatever is presented in the 
thymus/bone marrow during negative selection’ rather than being taken literally. Furthermore, the 
presence of infection-related signals is a necessary condition for T-cell activation 
providing an additional mechanism that assures tolerance to ‘self’ [23]. Sometimes 
described as contrasting [24], one could combine central and peripheral tolerance by 
stating that the immune system achieves self/non-self specificity by recognizing as ‘self’ 
‘everything that is presented in the thymus/bone marrow during negative selection or recognized without 
simultaneous signs of infection’. 
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1.1.3 TCR-pMHC interactions and T-cell activation 
The positive selection of T-cells is based on their capacity to recognize pMHCs rather 
than controlling only for the proper folding of the receptor as in the case of the BCRs 
[20,25]. This is explained by the strict MHC-restriction of T-cell responses, in which TCRs 
recognize a mixed surface composed by the MHC peptide-binding cleft and the presented 
peptide [1,11,26,27]. In order to be recognized, a presented ‘foreign’ peptide must 
therefore sufficiently transform the mixed surfaces encountered during negative selection 
– a phenomenon aptly described as ‘altered self’ before many of the structural details were 
established [28]. In the case of alloreactivity, T-cells encounter MHC-peptide interfaces 
that are sufficiently different from the ones encountered during negative selection but 
sufficiently similar to the ones encountered during positive selection [29].  
 
It is interesting to note that alloreactivity has been implicated in the evolution of the 
adaptive immune system, e.g. [30-32], as it could be argued to be one of the characteristics 
that most critically depends on MHC restriction and its individualization of the unit of 
presentation.  
 
The exact binding requirements and nature of the outside-in signaling of TCRs are still 
not exactly understood (e.g. how the T-cell is triggered). Regardless, productive recognition 
of pMHCs by a naïve T-cell is required for activation, leading to clonal expansion and the 
killing of target cells, which carry appropriate pMHCs by primed CTLs [33,34]. Notably, 
this process is not binary and different degrees of T-cell activation can result from 
differences in ligand density and/or TCR-pMHC interactions [35-38]  (See 1.3.2ff).  
1.2 More	  details	  about	  selected	  features	  of	  MHC-­‐I	  antigen	  presentation	  
1.2.1 Molecular details of peptide binding by MHC-I 
Although this section intends to focus on the details of MHC class I-restricted peptide 
presentation, it should be noted that several of the structural and biophysical features that 
define peptide binding and presentation by MHC-I also apply to MHC-II [39]. X-ray 
crystallography has played, and still plays, a crucial role in the understanding of the 
molecular details underlying MHC antigen presentation and TCR-pMHC interactions. A 
number of remarkable contributions have provided detailed understanding of prevailing 
and/or competing hypotheses (see refs [40,41] for a short perspective on the first pMHC 
and TCR-pMHC structures). The first three-dimensional X-ray structure of an MHC-I 
molecule revealed the molecular architecture of HLA-A0201 and its novel peptide-
binding domain [4] (Figure 1a). Most importantly, and despite the fact that it was not yet 
possible to determine the structure of individually bound peptides, this pioneering work 
by Pamela Bjorkman and Don Wiley provided the first structural description of peptide 
binding and a striking rationalization of MHC-restriction as well as the phenomenon of 
‘altered self’ (Figure 1b). The crystal structure demonstrated that the pMHC complex 
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present a mixed interface, composed of the MHC heavy chain (‘self’) combined with the 
potentially foreign peptide, to the TCR [4,11]. Additionally, it clarified the role of the β2-
microglobulin light chain (β2m) as a non-covalently bound support molecule for the 
heavy-chain β sheets, which provide structural support to the peptide-binding cleft. The 
Bjorkman study demonstrated that polymorphisms between MHC alleles and isotypes 
could largely be mapped to the peptide-binding cleft. Consequentially, it was inferred that 
different MHC molecules have different peptide-binding preferences, presenting different 
peptide repertoires [4,11]. As differences in the peptide repertoire are expected to result in 
a distinct ‘self’ repertoire presented during the acquisition of tolerance, this study provided 
a compelling structural explanation for the observed correlation between MHC 
heterogeneity and alloreactivity in transplantation success [4,9,11,42]. A fascinating twist to 
this theme was provided by two recent studies, both of which demonstrated how a drug 
can cause autoimmunity through direct interaction with the peptide-binding cleft of HLA-
B*57:01, thus altering the peptide repertoire presented in the periphery [43,44].  
 
Structurally, the membrane-bound polymorphic heavy chain of MHC-I forms a 
heterodimer with the relatively conserved β2m. The MHC-I heavy chain consists of the 
three extracellular domains α1, α2 and α3. The α1 and α2 domains form the peptide-
binding groove through the assembly of eight antiparallel β-sheets whose edges are lined 
by two broken α-helixes. The formed groove, correctly assumed as the peptide-binding 
cleft [11], is oriented away from the cell membrane and thus perfectly suited for the 
presentation of peptide antigens to the immune system. The relatively more conserved α3 
domain and the β2m subunit form the base of the MHC heterodimer, connecting the 
peptide-binding groove to the transmembrane domain of the heavy chain (Figure 1a,b).  
 
The subsequent determination of the crystal structures of different MHC-I alleles in 
complex with an array of immunodominant peptides [5,45-52] (Figure 1c) combined with 
the increased understanding obtained from the elution and sequencing of MHC-I bound 
peptides [53,54], allowed for a more detailed description of the rules that govern peptide 
binding by different MHC-I alleles as well as some general principles underlying TCR-
recognition [55-60]. The peptides are tightly anchored to the MHC binding-groove 
through interactions between specific peptide side chains and MHC residues that co-
localize in more or less deep pockets [42] (Figure 1c). The pockets have different sizes and 
chemical properties in different allelic variants of MHC class I molecules. Thereby they 
impose distinct sequence constraints on the presented peptides and determine that class I 
binding peptides are characterized by allele-specific sequence motifs. At least two of these 
peptide-binding pockets, of which one always localized at the C-terminus of the peptide, 
define the main anchor motif of the alleles and are highly selective for specific side-chains 
[39,61] (Figure 1c). While the main anchor residues contribute disproportionally to the 
strength of MHC-peptide interactions [62], it is important to point out that the entire 
length of the peptide makes extensive contacts with the peptide-binding cleft and that 
secondary anchor residues play  
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Figure 1: Peptide presentation by the MHC-I 
A) Representation of the first MHC-I crystal structure revealing its unique peptide-binding 
cleft, the "1, "2, "3 domains (yellow, salmon and blue, respectively) and the !2m light chain 
(white). The molecule is displayed from the side with the truncated transmembrane domain 
oriented downwards. B) The electron density of the peptide binding cleft from the same 
structure is displayed in blue and the MHC shown from the perspective of the TCR. The 
electron density that was correctly assumed to represent bound peptides (red) provides a 
visualization of the concept of ‘altered self’. C) H-2Kb/FAPGNYPAL, one of the first 
structures of an MHC-I molecule in which an individual peptide could be modeled. The 
peptide-binding cleft is displayed from the side, visualizing how the peptide (blue; electron 
density in red) is anchored to the MHC  through specific side chains (white stars) while other 
side chains point towards the TCR. D) Surface representation of a pMHC (same orientation as 
in B), demonstrating how the entire peptide (blue) makes extensive contacts with the peptide-
binding cleft (grey). E) Left panel: Superposition of a selection of peptides determined in 
complex with Db that highlights the conserved position of the buried side chains (grey; main 
anchor residues underlined) as well the significant flexibility of the rest of the peptide (blue). 
Right panel: Same complexes shown from the perspective of the TCR to illustrate how the 
exposed side chain generate a unique antigenic identity for each pMHC complex – the altered 
self. Figures A, B and C have been reproduced with permission from [4] and [5], respectively. 
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an important role in tuning MHC-peptide interactions (e.g. refs. [58,60,63,64]) (Figure 1d). 
Consequently, it is important to note that the MHC-I binding affinity and stabilization 
capacity of peptides containing the preferred main anchor residues may range from 
extreme binding to very weak or no binding at all depending on their overall sequence. 
 
In contrast to the buried anchor residues, large parts of the bound peptides display 
significant conformational freedom, with some of the peptide side chains pointing away 
from the MHC binding groove (Figure 1e). These residues generally contribute less to the 
allele-specific binding motif and are thus variable in both sequence and conformation. As 
a result, each peptide provides a unique chemical and conformational antigenic identity 
[45] to the mixed interface of MHC and bound peptide (Figure 1e). In conclusion, each 
presented peptide has side chains that point towards the peptide-binding grove, defining 
MHC-binding and residues pointing away, defining the antigenic identity. Additionally, 
several of the secondary anchor residues are sufficiently exposed to be able to contribute 
to the antigenic identity of the peptide and vice versa, stressing that there is no defined 
separation between the two roles (see 1.3.1).  
1.2.2 Short introduction into MHC-I restricted antigen processing 
Although, not the focus of this thesis, some principles of MHC-I antigen processing will 
be summarized here below, given its central role in antigen presentation and CTL priming 
in vivo (detailed descriptions and discussions of antigen processing are provided in e.g. 
[12,13,65]). In order to act as a ‘window into the cell’, MHC-I presents endogenous 
peptides derived for example from proteasomal and defective ribosomal translation 
products (DRiPs, defective ribosomal products) in a process that is dependent on TAP 
(transporter associated with antigen processing) and a whole range of proteasomes and 
chaperones, finally resulting in the assembly of pMHCs in the endoplasmic reticulum. 
Additionally, uninfected pAPCs have the capacity to cross-present exogenous antigens on 
MHC-I molecules thereby cross-priming CTLs with antigens delivered to the lymph node 
[66-69]. This seems to play a crucial role in the fast activation of T-cells without prior 
infection of pAPCs in the lymph nodes and allows the priming of CTLs specific to TAAs 
[70]. Additionally, and although the in vivo relevance of this process is only beginning to be 
established [71,72], pAPCs can directly acquire pMHCs from infected cells [73], a 
phenomenon termed cross-dressing [70]. 
 
All together, the details of cross-dressing, cross-presentation and of other aspects of 
antigen processing, such as immunoproteasome activity and intracellular 
compartmentalization, have the potential to further modulate T-cell activation and 
introduce some degree of foreign antigen bias to antigen presentation, which has been 
generally (including above) described as non-specific [12,74-77]. Furthermore, gap-
junctions between cells have been demonstrated to be a source for MHC-restricted  
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antigens in target killing or cross-priming [78]. Finally, a number of studies have also 
reported and provided increasing examples of TAP-independent presentation of viral and 
tumor antigens, further increasing the complexity of endogenous class I antigen 
processing [79-83]. The ability of MHC-I molecules localized on the cell surface to bind 
exogenous antigens [84] is probably of limited relevance in vivo because of their low 
concentration, but should nevertheless be mentioned as this property forms the basis of 
the cellular MHC-I binding affinity and stability assays applied in Paper II. 
1.2.3 Stability and density of pMHCs on the cell surface  
As only a very small portion of the pMHCs can be expected to carry ‘foreign’ peptides, T-
cells require the ability to quickly scan a large number of pMHCs and the sensitivity to 
become activated by a highly limited fraction of cognate antigens (see 1.3.2) [85,86]. A 
defining feature of pMHC-I complexes is that the bound peptides are required for 
complex stability [84] and peptide-deficient MHCs rapidly disappear from the cell surface 
[87,88]. Therefore, the binding affinity of peptides, and most importantly, their MHC 
stabilization capacity determines the density and the half-life of pMHCs on the cell surface 
[87-89]. pMHC density and half-life in turn are important parameters that tune the 
activation of T-cells and thus MHC-I stabilization capacity contributes significantly to the 
immunogenicity and the immunodominance hierarchies of MHC-I restricted peptides 
antigens (see 1.3.3) e.g. [36-38,75,90-94]. As a rersult, peptides that are presented by a 
specific MHC but have very poor stabilization capacity can be expected to cause only 
limited deletion of T-cells during negative selection tolerance even if they are ‘self’ and in 
principle presented on MHCs. This is believed to contribute to the fact that many 
promising TAAs (defined through the identification of respective CTL clones) have low 
MHC stabilization capacity and directly related to the work presented in Manuscript I, 
which characterizes the enhancement of a poorly binding TAA that can be recognized by 
high-avidity CTLs [95-99].  
1.3 CTL	  activation	  with	  an	  emphasis	  on	  altered	  peptide	  ligands	  and	  
TCR-­‐pMHC	  interactions	  
1.3.1 Structural details of TCR-pMHC interactions 
The first X-ray crystal structures of ternary TCR-pMHC complexes provided the ultimate 
validation of the ‘altered self’ hypothesis for T-cell recognition [1,26] (Figure 2) and, 
together with subsequent studies, delivered detailed structural characterization of how 
TCRs recognize mixed MHC/peptide interfaces (see refs. [100-102] for comprehensive 
reviews). Limited buried surface area and shape complementarity generally characterizes 
the low-affinity TCR-pMHC complexes (Figure 2c). In general, TCRs bind MHC/peptide 
interfaces with a relatively conserved diagonal orientation centered on the middle part of 
the presented peptides. The diagonal binding mode of TCRs leads to a predominant, but 
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not exclusive interaction of the most variable, recombined third complementarity 
determining regions (CDRs) with the presented peptides. Conversely the germline-
encoded CDRs 1 and 2 generally interact more but not exclusively with the MHC 
commonly involving a set of specific exposed MHC residues, which are more or less 
conserved between allelic variants [103,104] (Figure 2). Accordingly, several ‘hot-spots’ on 
that contribute significantly to TCR-pMHC interactions have been identified on the 
MHCs [101] (Figure 2b). However, comparative structural analysis also demonstrated that 
CDRs display limited but important flexibility providing them with the capacity to adapt 
to pMHCs [105]. A beautiful study by Stephanie Gras et al. demonstrated how the capacity 
of TCRs to recognize a specific pMHC complex could be constrained by negative 
selection providing a structural visualization of the consequence of acquired tolerance 
[106]. Fittingly, a number of ternary X-ray structures of allo- and autoreactive TCRs 
suggested that their often-unusual binding modes are driven by thymic selection and by 
the deletion of conventionally binding TCRs [107]. Finally, a series of studies determined 
the X-ray structures of TCR-pMHC complexes in which functional differences were 
associated to limited structural changes and could not be directly correlated (see 1.3.3) 
[108-110].  
 
Despite the prominence of the central part of the peptide, it has to be stressed that 
potentially all peptide residues can contribute to the antigenic identity of the MHC-
restricted epitope and that it is still notoriously difficult to predict the consequences of 
peptide modification on TCR interaction unless done with a specific and structurally 
characterized TCR/MHC pair. Finally, it is also important to highlight that our current 
structural understanding of TCR-pMHC interactions is probably biased and incomplete. A 
few TRBV (TCR β variable chain) genes are strongly overrepresented in the relatively 
short list of determined TCR-pMHC structures as they are seemingly more amendable to 
protein crystallography. Namely, of the roughly 37 unique TCR-pMHC complexes, more 
than half of the TCRs contain either the murine TRBV13 Vβ domain or the highly related 
human TRBV6 Vβ domain (http://imgt.cines.fr [111]). Further studies that make use of 
molecular dynamic simulations (MD simulation), NMR (nuclear magnetic resonance), 
spectroscopy and several other methods generate important data that complements the 
largely static information provided by X-ray crystallography. These approaches have been 
used to characterize the dynamic aspects of MHC-bound peptides and TCR-pMHC 
interactions, which have been difficult to explain by X-ray crystallography. The research 
group of Brian Baker has provided several examples of such studies including the use of 
Deuterium exchange and MD simulations to analyze the mechanism for signaling in 
which TCRs lose flexibility upon binding to pMHCs [112]. Additionally, NMR, 
anisotropic fluorescence measurements and MD simulations have been successfully used 
to explain how the structurally conserved enhancement of a main anchor residue resulted 
in increased peptide flexibility, leading to disturbed rather than increased TCR binding 
[113,114].  
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Figure 2: Classical TCR binding of pMHCs  
A) The three-dimensional ternary structure of one of the two first TCR-pMHC 
complexes to be determined reveals how the TCR interacts with its six CDRs (colored 
individually) with the MHC-peptide interface. B) Representation of the TCR-pMHC 
complex from the perspective of the TCR. The variable domains of the TCR are 
displayed (V" in blue, V! in red) and bind to the pMHC (MHC in grey, peptide in yellow) 
in the generally conserved diagonal docking mode, which is centered around on 
conserved MHC contact residues (cyan) and the highly exposed peptide side-chain in the 
middle of the peptide. C) Representation of how the six CDRs (CDRs "1-3 in light blue, 
blue and dark blue, respectively; CDRs !1-3 in salmon, red and dark red, respectively) of 
the TCR interact with the pMHC shown from the top (left panel) and from the side 
(right panel). This figure highlights how the most variable third CDRs are focused on the 
exposed central part of the peptide, while also providing an understanding of the limited 
surface complementarity between the TCR and pMHC as particularly the CDRs !1 and 
!2 make almost no interaction with the pMHC complex in this specific ternary complex. 
Figure A is reproduced with permission from [1] 
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1.3.2 Kinetics, energetics and specificity of the TCR-pMHC interaction  
In addition to structural characterizations, the affinity, kinetics and thermodynamics of 
TCR-pMHC interactions have been studied extensively on soluble molecules [117-119] 
and increasingly using systems that mimic aspects of the cellular context of in situ TCR-
pMHC interactions [120-123]. Invariably, measurements with soluble molecules capture 
only some aspects of the multi-facetted interactions between T-cells and APCs, perhabs 
explaining why extensive characterizations have not yet provided a universal relationship 
between T-cell activation and the kinetic and thermodynamic parameters underlying TCR-
pMHC interactions [118,119,124]. Nevertheless, crucial insights have been gained from 
these in vitro studies, which remain tremendously useful in order to characterize 
differences within the TCR recognition of specific sets of MHC-restricted peptides. 
Accordingly, surface plasmon resonance (SPR) and isothermal titration calorimetry (ITC) 
was an important part of the characterization of TCR recognition of modified peptides 
performed in Paper II and Manuscripts I and III. 
 
SPR and ITC studies revealed that the binding of TCRs to pMHCs is characterized by 
relatively weak affinities and fast kinetics with KD values stretching from 1 µM to about 
30-70 µM, for strongly and weakly activating interactions, respectively [117]. Awareness of 
these small differences highlights the extreme specificity of T-cell recognition and the fact 
that TCR-pMHC interactions are tuned to translate extremely subtle changes in free 
binding energy and kinetics into an entire spectrum of functional outcomes e.g. 
[108,119,125-127]. Fittingly, the study presented in Paper II provides a thermodynamic 
characterization of a TCR-pMHC interaction in which the removal of a hydroxyl group at 
the tip of the main TCR-interacting peptide residue abolished functional recognition. 
Additionally, this study and Manuscript III describe peptide variants in which very small 
affinity differences correlate with significant differences in CTL activation. 
 
This extreme specificity is particularly striking given that TCRs are also considerably cross-
reactive, with the ability to structurally adapt to different pMHC complexes (see recent 
reviews [101,128] and references therein). These two features represent two central 
requirements of the adaptive immune system in which cross-reactivity seems to be 
necessary in order to allow a limited repertoire of TCRs to recognize a virtually unlimited 
variety of antigens [128,129]. Conversely, extreme specificity is an absolute requirement, 
given that the difference between ‘self’ and a vast number of ‘foreign’ antigens is only 
defined through very small differences in the significantly conserved MHC/peptide 
interface. This specificity together with the absence of affinity maturation also seems to 
explain the relatively low affinity of the TCR-pMHC interaction. In addition the 
requirement of TCRs to transiently interact with a large number of pMHCs demand that 
the TCR-pMHC interaction is governed by fast kinetics, which might have also played a 
role in preventing higher affinities of TCRs towards pMHCs.  
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The apparent contradiction between specificity and cross-reactivity can probably be 
resolved by suggesting that TCRs are extremely sensitive to very small changes in exposed 
peptide residues in the context of one specific pMHC-TCR complex, whereas 
conservation of the MHC surface and characteristics of the TCR paratopes following 
thymic selection allows the same TCRs to also specifically recognize other, possibly very 
different, pMHCs [101,105,128,130-136]. Hence, the term ‘polyspecificity’ has been 
suggested as more appropriate than ‘promiscuity’ or ‘cross-reactivity’ [137].  
1.3.3 From pMHC recognition to CTL activation 
With the perplexing results of Ding et al., and similar studies, which essentially 
demonstrated that the tenary structures of several TCR-pMHC could not explain their 
functional differences, it became clear that the molecular basis of outside-in TCR signaling 
was not straightforward [108-110]. While still not completely understood, T-cell triggering 
is an extremely lively area of research and a number of recent publications have shed more 
light on this process and convincingly implicated direct signaling [112,138], clustering of 
co-stimulatory molecules CD4 and CD8 [139,140], the geometry of pMHC-TCR 
interaction [141], the cytoskeleton [121,142] as well as adhesion- and other cell-surface 
proteins [120,143]. Aside from the actual triggering, it should be noted that a whole range 
of additional factors, including glycosylation [144] as well as cell surface clustering of 
TCRs and pMHCs [74,145,146] are expected to tune T-cell activation in vivo [147].  
 
CTL activation is highly dependent on cognate pMHC ligand density. With that in mind 
and facing the enormous complexity described above when defining TCR-pMHC 
interactions in vivo, the somewhat fuzzy terms ‘functional avidity’ or ‘recognition 
efficiency’ are highly useful as they ignore most of the molecular details and simply 
describe the capacity of a CTL to react to a specific pMHC dose under specific conditions 
(see for example ref. [148]). 
 
Even if the molecular details remain unclear it is evident that in order to result in T cell 
activation, the interactions between TCRs, co-receptors and pMHCs must generate 
sufficient levels of phosphorylation of the intracellular part of the TCR-complex. This is 
essential for the priming of naïve T-cells by activated DCs and will ultimately result in the 
killing of target cells by activated effector CTLs. The main outcomes of the priming of 
naïve CD8+ T-cells include clonal proliferation of the activated CTLs, up-regulation of 
CD8 and cell surface adhesion molecules, as well as homing to inflamed tissues. 
Prolonged interaction of TCRs on activated CTLs with cognate pMHCs on target cells 
will initially lead to tighter interactions with target cells, accompanied by a significant 
polarization of the CTLs, resulting in the formation of an immunological synapse between 
the two cells [149] (Detailed reviews of T cell signaling, priming and effector functions can 
be found in refs. [33,34]). This in turn assures that the subsequent effector functions, 
aimed at inducing the death of the recognized cell, are efficient and spare surrounding 
uninfected cells. The differential expression of intra-, extracellular and secreted proteins 
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that mediate and accompany the differentiation and the effector functions of CTLs 
provides important markers that allow the characterization of lymphocyte populations.  
1.3.4 Modulation of T-cell activation by altered peptide ligands 
Important insights into T-cell activation and TCR-pMHC interactions were derived from 
the understanding that T-cell activation was not a binary process, and that small changes 
to the presented peptides could gradually affect both the range and magnitude of priming 
and effector functions [127,150]. Classical altered peptide ligands (APLs) displayed 
modifications in TCR-contacting residues thereby affecting the functional avidity of 
CTLs. Starting from an agonist, a peptide that evokes optimal responses in its cognate 
CTL, modifications can reduce responses (weak/partial agonist), elicit no responses (‘null 
peptide’) or even antagonize CTL responses. Additionally, this terminology can also be 
useful to describe variants of immunodominant viral epitopes with respect to specific 
CTLs that generally strongly dominate the immune response [151]. Paper II explores how 
APLs modulate TCR recognition and in particular how a specific TCR interacts and 
recognizes both its cognate agonist pMHC and an altered semi-agonist variant.  
 
In conclusion, the functional avidity of a CTL defines the pMHC density required to cross 
a signaling threshold of activation (and vice versa). However, this threshold is not binary 
but, within limits, priming and activation of effector function display a dose-response 
behavior. It should be expected that sensible ranges of pMHC density and functional 
avidity are more narrow in vivo than in vitro, thus introducing qualitative limitations to this 
quantitative relationship. Distinct influences of quality vs quantity on T-cell activation 
within that window have been suggested for CD4+ T-cells [152] but, to my knowledge, 
not demonstrated for CTLs.  
1.3.5 Principles and examples of APLs with enhanced CTL recognition and obstacles 
of elicitation in vivo 
The use of APLs has been extended to enhance the immunogenicity of viral escape 
variants and particularly of poorly immunogenic TAAs. The underlying assumption is that 
tumors, while not immunogenic, are in principle antigenic and can be targeted by properly 
activated T-cells [153]. 
 
The immunogenicity of MHC-restricted peptides can be enhanced with the aim to directly 
increase TCR recognition and the functional avidity of elicited CTLs against native 
epitopes e.g. [154,155]. Alternatively, the MHC-binding properties of TAAs can be 
enhanced in order to increase pMHC density and thus lower the threshold of functional 
avidity required for activation. This seems particularly applicable to TAAs as many 
promising candidates have weak MHC-binding properties, likely limiting their 
presentation during negative selection (see 1.2.3). An interesting consequence of the 
central role of pMHC density, which is important for the use of peptides in 
 
 
 
14 
 
 
 
immunizations, is that increased peptide doses can elicit CTLs with decreased functional 
avidity, probably by lowering the avidity threshold of activation and the exhaustion of 
strongly activated CTLs [156-158].  
 
The aim of peptide enhancement is to elicit more potent responses against native TAAs 
or viral epitopes presented on target cells. This focus on elicitation deviates somewhat 
from the original context of APLs and one could argue that this approach somewhat 
echoes a central obstacle in the design of APLs. Namely, it is becoming increasingly clear 
that the enhancement of in vitro epitope immunogenicity with respect to a small number of 
CTLs that are specific to the native epitope (termed here cross-recognition) does not 
necessarily result in the increased elicitation of CTLs with high functional avidity against 
the native epitope (termed here cross-elicitation) in vivo e.g.[159-163].  
 
 
Strictly applying the principle that minor anchor residues can significantly contribute to 
MHC-binding, the results presented by van Stipdonk et al. described an unconventional 
modification at position 3 of the Db restricted gp100-derived TAA EGS 
(EGSRNQDWL), which is significantly overexpressed in malignant melanoma [164,165]. 
EGS has very poor MHC stabilization capacity and is poorly immunogenic even though it 
contains the optimal main anchor motif for Db [164,166]. A surprisingly large increase in 
immunogenicity was measured when the serine residue at position 3 of EGS was 
exchanged to a proline (EGP). The MHC stabilization capacity of the modified EGP 
epitope was dramatically enhanced and most crucially, vaccination with EGP cross-elicited 
potent CTL responses against the native epitope EGS on melanoma cells [164]. 
 
Manuscript I investigates the molecular mechanisms underlying the strong impact of p3P 
in Db-restricted peptides on MHC stabilization capacity; expanding the current description 
of minor anchor residues for this allele. Importantly, this study indicates that the p3P 
modification has an unforeseen and direct effect on TCR affinity that is independent of its 
impact on MHC binding. Additionally, Manuscript III describes the application of the 
same modification to increase the immunogenicity of the Lymphocytic Choriomeningitis Virus 
(LCMV)-derived Db-restricted epitope gp33 (KAVYNFATM) and of the naturally 
occuring escape variant Y4F (KAVFNFATM) [151]. Importantly and in contrast to the 
TAA EGS, both gp33 and Y4F already display strong MHC stabilization capacity. 
Nevertheless, the p3P substitution increased their immunogenicity both in in vitro and in 
vivo resulting in focused TCR recognition of Y4F following vaccination with the p3P-
modified peptide PF (KAPNFATM). 
 
In summary, these studies demonstrate that it is fully possible to enhance TCR 
recognition by using APLs with modified secondary anchor residues. 
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1.4 Introduction	  to	  HIV	  and	  SIV	  with	  a	  strong	  emphasis	  on	  antibody	  
neutralization	  
HIV is characterized by its high prevalence in endemic areas, the absence of universally 
practical and straightforward prevention and its uncontrollable mortality in the absence of 
treatment [167]. Furthermore, HIV represents a striking evolutionary adaptation, which 
prevents clearance from the host despite active viral replication and extreme pathology 
[168,169]. As a lentivirus belonging to the Retroviridae family, HIV relies on a highly 
error-prone polymerase for the initiation of replication and therefore produces substantial 
diversity in each cycle of replication [168]. This allows the virus to continuously evade 
immune responses and display considerable variation during the course of infection [169].   
 
AIDS (acquired immunodeficiency syndrome) is a direct consequence of HIV/SIVs 
predominant infection and depletion of CD4+ T helper cells in the host [168,170]. Target 
cell recognition and fusion are mediated by the multimeric, glycosylated cell surface 
protein complex (Env) in HIV and its simian counterparts SIV [171] (Figure 3). The Env 
subunits gp41 and gp120 (glycoprotein 41 and 120, named after their respective molecular 
masses) are the only cell surface proteins and thus the most exposed targets for antibody-
mediated immune responses, which can neutralize the virus by preventing interaction 
and/or fusion with target cells [171]. The continuous replication of HIV results in 
constant exposure to immune recognition and the virus is accordingly subjected to strong 
selection pressure from antibody and T-cell responses until the host’s immune system 
eventually collapses [172]. This selection pressure is reflected in specific viral adaptations 
and the extreme variability of Env, which together have proven successful in impairing 
immune responses and vaccine efforts alike [171,173-176]. Furthermore, the variability of 
HIV has resulted in significant plasticity of Env as the virus meets shifting selection 
pressures from transmission to peak viremia and persistent infection and ultimately to 
AIDS [177-182]. 
 
The development of highly active antiretroviral therapy (HAART) against HIV efficiently 
prevented disease progression and dramatically changed the life of those infected [183]. 
Despite this huge success for drug design and the recent improvements in drug availability 
in poorer countries, HIV still has a dramatic prevalence in certain parts of the world and 
the associated mortality and morbidity cause extreme socio-economic damages to affected 
societies [167]. A significant number of effective prevention strategies and factors 
decreasing the spread of HIV have been described, including HAART, condom use, male 
circumcision, treatment of other sexually transmitted disease, pre- and post exposure 
prophylaxis, education, women’s empowerment, stable family structures as well as social 
stability [167,184]. However, the failure and inherent difficulties of their implementation 
as well as the financial costs, the occurrence of drug resistance and the side effects of 
HAART, together with the precedence of the global vaccination campaigns against Polio 
and Smallpox, provide continuous motivation for the development of a vaccine against 
HIV. Essentially, these efforts have encountered the same challenges as did our immune 
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system and success is likely to require a combination of ‘simply’ trying, characterizing the 
most relevant targets and improving our understanding of the immunological principles 
underlying B-cell activation [173,185-187].  
 
Although the HIV-2 variant shares its genome structure and main proteins with HIV-1, 
significant differences nevertheless exist between the two [188]. HIV-2, which is believed 
to have crossed independently to humans, is endemic mainly in West Africa [188]. 
Overall, HIV-2 causes a relatively less aggressive infection, mainly characterized by 
decreased virema, slower and less certain progression to AIDS associated with reduced 
CD4+ T-cell loss and decreased infectivity [188-190]. Notably, HIV-2 is more susceptible 
to NAbs in vitro and more commonly neutralized by concurring autologous NAbs isolated 
from patients [191,192].  
1.5 	  Antibody	  responses	  against	  HIV/SIV	  Env	  and	  viral	  evolution	  in	  the	  host	  
1.5.1 Env structure and function  
The Env complex is a hexamer consisting of trimers of gp41/gp120 heterodimers, with 
gp41 spanning the viral membrane and gp120 facing target cells. Each Env trimer has a 
mushroom-shaped form with a three-fold symmetry perpendicular to the cell membrane 
[175,193,194] (Figure 3a). The prominently exposed gp120 is the main target for antibody 
responses and contains several crucial structural elements. It consists of a conserved site 
for interaction with gp41 and trimerisation, a variable outer face, a number of variable 
regions and two highly conserved binding sites [171,175,194] (Figure 3d). Furthermore, 
gp120 is highly glycosylated, flexible and a large proportion of its secondary structure is 
undefined [175]. Out of the five variable regions V1-V5, V4 and V5 are real loops that 
make up a significant part of the variable outer face of gp120 (Figure 3c,d) and play an 
important role in NAb escape (see 1.5.2). The V1/V2 region is highly variable, 
glycosylated and seems to display considerable flexibility with respect to the core domain 
of gp120 [195-197]. Although it has been called the ‘V1/V2 loop’, its size of roughly 70 
amino acids and its three-dimensional crystal structure [197] strongly indicate that 
‘domain’ or ‘region’ are more appropriate terms. The main function of the V1/V2 region 
is to shield the rest of the gp120 molecule, including the V3 region, from antibody 
recognition (Figure 3d). Furthermore, the V1/V2 region has also been implicated in direct 
interactions with integrins on target cell membranes [198]. As for V1/V2, the V3 region 
has also been referred to as ‘loop’ but it has been convincingly argued that ‘region’ is more 
appropriate based on similar arguments [199]. The V3 region is believed to extend 
towards target cells following initial interaction with CD4 (Figure 3f) [200,201 {Liu, 2008 
#287]. It plays an important role in viral tropism and while parts of its 35 residues are 
highly variable, it contains significantly conserved elements, including the signature motifs 
GPGR or GPGQ at the tip of its extended structure [202]. Binding of gp120 to CD4 and 
to the chemokine receptors CXCR4/CCR5 is mediated by two distinct and highly 
 
 
 
17 
 
 
 
conserved binding sites on gp120 and is a prerequisite for large structural rearrangements 
that lead to membrane fusion driven by coiled-coil formation by gp41 [203].  
1.5.2 Immune evasion from antibody responses against Env 
HIV Env features an impressive array of antibody evasion mechanisms including heavy 
glycosylation and the dominance of highly variable regions on the exposed faces of gp120 
[171,175]. Furthermore, the conserved receptor interaction sites are hidden and inherently 
flexible, requiring CD4 binding to stabilize gp120 at a significant entropic cost [204]. This 
stabilization exposes the CXCR4/CCR5 binding site, which in turn is therefore only 
available for binding in great proximity to the target cell membrane, sterically preventing 
antibody neutralization (Figure 3f) [174,193]. Additionally, only a few copies of the Env 
trimer are expressed on the cell surface, potentially hindering bivalent antibody binding 
[205]. Finally, the functional Env trimer is highly unstable and the released gp120 
monomers can cause antibody responses against sites that are buried within the functional 
Env complex [206].  
 
As a consequence of this adaptation, NAb responses against HIV, which are generally 
observed with a significant delay and fail to suppress the infection [207]. The majority of 
the elicited antibodies are directed against monomeric gp120, non-neutralizing sites or 
highly variable parts of Env [207,208]. Nevertheless, it is important to note that a number 
of well-described epitopes targeted by very broad NAbs (the term ‘broad’ generally 
describes the ability to cross-neutralize heterologous viruses, including isolates that are less 
sensitive to neutralization) have been identified [174,209-211]. Examples of such 
conserved epitopes comprise quaternary epitopes on the V1/V2 and the V3 regions, 
specifically on a site that has been implicated in binding to integrins on the target cells 
[198]. Additionally, the CD4 binding site (CD4bs), the MPER (membrane proximal 
external region) and even conserved glycans are targeted by very broad NAbs. 
Interestingly, while it is believed that a significant fraction of patients eventually develops 
broad NAb specificities, these are generally observed late and fail to significantly impact 
disease progression [207,212]. These broad NAbs all display extensive affinity maturation 
and other features such as above-average CDRH3 lengths and high hydrophobicity that 
together explain their rare and late occurrence [213-216]; reflecting the potent evasive 
properties of the Env proteins.  
 
Crystal structure analysis combined with mutational and biophysical studies of broad 
NAbs have provided a deep understanding of their mechanism of action as well as of their 
specific features (see or example refs. [185,204,217-219]). NAbs that efficiently target the 
V3 region are of particular interest to the work presented in this thesis (Papers IV and V; 
Manuscript VI). Recognized very early for its immunodominance, the V3 region elicits 
high titers of antibodies, including NAbs [195,220]. Generally however, these NAbs are 
highly specific and bind mostly to variable regions of the V3 region. Nevertheless, NAbs 
with some degree of breadth and potency, particularly against the conserved 
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GPGR/GPGQ motif, have been identified [220-223]. X-ray structure determination of 
the human anti-V3 antibody 447-52D in complex with peptide from the V3 region [218] 
demonstrated that this antibody makes an unusually high proportion of direct contacts 
with the backbone of the gp120 molecule around the GPGR/GRGQ motif, which allows 
it to defy some degree of sequence variation. Additionally, a number of other NAbs with 
considerable breadth and potency have been recently isolated and demonstrated to bind a 
quaternary epitope formed by V3 and V1/V2 [220,223]. Another interesting example is 
represented by the group of NAbs that bind to the conserved CD4bs and display highly 
potent and broad neutralizing activity, [185,217,224]. The extreme sterical hindrance from 
glycans and the V1/V2 region that antibodies have to overcome upon binding to the Env 
trimer (Figure 3d) was revealed by the crystal structure of b12, the first member of this 
group, in complex with monomeric gp120 [225] and subsequently based on Env 
structures determined with cryo-electron microscopy (cryo-EM) [226]. Using 
thermodynamic measurements it was demonstrated that a decisive feature of b12 and 
similar NAbs was the capacity to recognize only a specific fraction of the CD4bs. This 
allowed the antibody to bind to gp120 without the entropic penalty associated with the 
binding of CD4 and non-neutralizing antibodies to the CD4bs [217,224,227,228]. 
 
As previously mentioned, HIV-2 is generally less resistant to NAbs in vitro and more 
successfully controlled in vivo compared to HIV-1. This feature has been associated to a 
less potent shielding by the variable regions [188,229]. Unfortunately, still relatively few 
comparative studies have been performed to adequately address the mechanistic 
differences and evolutionary adaptations that underlay the observed differences in NAbs 
resistance. Particularly, the three-dimensional structure of the HIV-2 gp120 (HIV-2gp120) 
molecule has so far not been determined and comparative thermodynamic studies that 
would address entropic masking have not yet been performed. 
1.5.3 Antibody pressure and the evolution of HIV/SIV in the host 
While this introduction focuses on the direct evolution of Env in response to antibody 
pressure, it should be noted that HIV and SIV also adapt to CTL responses and possess 
several other immune evasion mechanisms unrelated to Env [187,230]. The extreme 
variability of HIV and SIV as well as the specific adaptations of Env allow the viruses to 
continuously escape from NAbs produced by the host [172,174]. This ‘evolvability’ is 
concentrated to the large proportion of loops and regions on Env (Figure 3c) that can 
vary significantly in both sequence and length [177,231,232]. Additionally, Env displays 
considerable variation in both amount and localization of glycans, with an increase 
generally associated with escape from antibody responses [181,231-233]. Finally, the 
degree to which conserved functional regions, such as the CD4 and coreceptor binding 
sites, are sterically masked in the functional trimer can vary. 
 
 
 
19 
 
 
 
 
Figure 3: Key properties of HIV Env 
A) Electron microscopy reconstruction of HIV particles with the trimeric ‘Env 
(blue) on the viral membrane. B) Schematic representation of the events preceding 
target cell fusion. Interaction of Env (red) with CD4 (yellow) results in a 
conformation change in Env (purple), leading to interaction with the chemokine 
receptor (green). C) Molecular model of the core domain of gp120 including the 
V3. The molecule is colored according to secondary structure highlighting the 
high proportion of unstructured regions D) Left panel: Hypothetical model of 
gp120 in trimeric Env prior to CD4 binding. The variable inner and more 
conserved outer faces are colored in light and dark grey, respectively. The V1/V2 
stem, the V3 region, V4 and V5 as well as the CD4bs are colored in red, green, 
purple, cyan and yellow, respectively. Right panel: A hypothetical model of the 
V1/V2 region (red) and predicted glycans (sand) have been added to visualize the 
extreme shielding of gp160. E) 3D cryo-EM reconstruction of Env (blue) to 
which crystal structures of gp120 (colored as in D) have been fitted. F) Cryo-EM 
with fitted X-ray structures before (closed) and after (open) CD4 engagement. 
CD4 binding leads to a rotation of the monomers resulting in exposure of the V3 
and sites associated to chemokine receptor binding. Figure A, E and the left panel 
of F have been reproduced from [2] under the creative commons attribution 
license; Figure B has been reproduced with permission from [3]. 
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While there is conflicting evidence on whether the virus that is transmitted and establishes 
the infection displays inherently increased neutralization sensitivity [208,234,235], it has 
become evident that transmission is mediated by a single or very few viral species 
[208,236]. Additionally, it has also been demonstrated that the rapid onset of variation in 
Env is at least partially driven by antibody responses and but appeared to be constrained 
by the need to maintain replicative capacity [178,180] A potential trade-off between 
replicative capacity and antibody resistance has also been suggested as laboratory-adapted 
HIV strains, in contrast to primary HIV isolates, display strongly increased neutralization 
sensitivity and seem overall more adapted for in vitro replicative capacity [237]. 
Interestingly, these features were reflected to some degree in changes observed upon 
comparing HIV isolates from patients suffering from AIDS and those that are chronically 
infected. HIV isolates from AIDS patients display reduced glycosylation, increased 
neutralization sensitivity and increased in vitro replicative capacity correlated with changes 
in electrostatic surface potential and reduced glycosylation [229,238] and Paper VIII.  
 
A fascinating and somewhat worrying recent addition to the described plasticity of Env 
was provided on the basis of a comparison between the neutralization sensitivity of 
primary isolates that were obtained at similar times after infection but 15 years apart 
[176,239]. These studies demonstrated that over the course of 15 years HIV-1 has evolved 
significantly decreased neutralization sensitivity. The decreased neutralization sensitivity 
was correlated to increases in the length of both V1/V2 and V4 loops as well as to the 
amount of predicted glycosylation sites. Interestingly, the increased neutralization 
resistance was accompanied by an overall decrease in the potency and breadth of NAbs 
produced by the respective patients [176]. Finally, very similar changes to gp120 were 
found when comparing the sequences deposited in the global HIV sequence database 
from corresponding years. 
 
In conclusion, HIV/SIV successfully evades humoral immune responses against the 
highly conserved epitopes on Env through the extreme variability and specific adaptations 
of the envelope proteins. This ability generally results in the failure of the host to mount 
effective NAb responses, while also providing tremendous challenges to vaccine 
development. Finally, recent evidence suggests that HIV has over the years of the 
epidemic evolved its resistance to human antibody responses without evident loss of 
infectivity.  
 
1.6 HIV	  vaccine	  efforts	  
1.6.1 HIV Env immunogen design and the main obstacles to HIV vaccine efforts 
The following section will attempt to describe previous and ongoing efforts to generate 
prophylactic antibody-based protection against HIV-1. It should however, be noted that 
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other prophylactic measures such as pre- and post exposure prophylaxis as well as 
microbicides are also being investigated and have shown some promises [184,240]. 
Although not addressed in the frame of this thesis, it is furthermore conceivable that T-
cell responses will contribute to a prophylactic vaccine and T-cell based immunogens thus 
seem strong candidates for therapeutic applications [208].  
 
The use of attenuated viruses as immunogens is being explored and although they 
promise some effectivity, this approach is generally considered unsafe due to high risk for 
reversion to pathogenicity [241]. Therefore, most efforts have been focused on the use of 
recombinant forms of gp41 and gp120 as immunogens and particularly on the design of 
stable gp140 trimers. These recombinant trimers, which consist of gp120 and the 
extracellular part of gp41, are intended to mimic functional Env with respect to overall 
structure as well as disposition and accessibility of NAb epitopes. The resulting efforts 
have led to the elicitation of increasingly potent and broad NAb responses in small animal 
models and non-human primates [242-245]. Additionally, the development of increasingly 
sophisticated DNA-prime protein-boost vaccination strategies has improved the outcome 
of immunizations [246,247]. Nevertheless, despite these achievements none of the 
immunogens and vaccination strategies tested so far has resulted in the elicitation of truly 
broad and potent NAbs [245]. This seems entirely reasonable (admittedly in retrospect) 
considering the ability of the virus to successfully evade immune responses, the long time 
it requires for patients to mount broad NAbs, and the potential bias resulting from 
different CDR repertoires in animal models and humans [207]. More specifically, one 
could argue that the design of immunogens is constrained by an underlying conundrum in 
that those with facilitated access to highly conserved epitopes should elicit neutralizing 
antibodies that are unable to recognize the epitopes in their native restricted context 
[173,187]. Conversely, the use of immunogens that fully mimic the restrictions of native 
Env is most likely to replicate natural exposure and -at least initially- simply not yield 
NAbs against conserved epitopes.  
 
Accordingly, current efforts are increasingly focused on the design of immunogens and 
vaccination strategies that take into account the unusual properties of broad NAbs that 
have been isolated from patients. Proposed strategies aim for example at the initial 
elicitation of antibodies with common precursors to the highly affinity-maturated CDRs 
generally observed in broad NAbs [185,207,213,215]. Additionally, it might be necessary 
to repeatedly boost the elicited antibody responses in order to maximize their 
neutralization capacity [248]. In parallel, increasingly intricate epitope-based immunogens 
are being designed with the aim to directly elicit potent NAbs [219,223,249,250]. Finally, 
novel ideas including the work presented in Manuscript VI as well as increasing 
understanding of optimal priming, adjuvants, delivery, vaccination strategies and 
combination with CTL responses will most probably provide crucial contributions to 
successful vaccines.  
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The study presented in Manuscript VI is unusual as DNA priming was boosted with a 
recombinant gp140 trimer that was derived from SIVmac239 instead of HIV. This strategy 
attempted to benefit from the comparatively higher stability of the SIV trimer and test if 
highly heterologous protein boosts would preferentially increase responses against highly 
conserved epitopes. The strategy resulted in the elicitation of comparably high-titer and 
potent NAbs in rabbits and thus provides a novel and promising platform for further 
optimization.  
 
Another important aspect of vaccine design against HIV is that the exact or minimal 
requirements for sterilizing immunity (the correlates of protection) are only beginning to 
be established. This has been highlighted by the results from the RV144 phase 3 efficacy 
trial, which was based on the use of a monomeric gp120 protein boost and reported some 
indications of efficacy [251,252]. The indicated protection is notable given that 
monomeric gp120 had been abandoned in immunogen design and is generally considered 
to not elicit broad NAbs in small animal or non-human primate studies. Accordingly, 
while relatively high but transient titers of NAbs were demonstrated in vaccinees, no 
broad NAbs were observed [253]. It seems certain that DNA priming was an important 
part of the protective responses, as earlier trials with similar recombinant proteins did not 
result in similar protection [245]. Additionally, the results from the RV144 study provide 
support for the argument that antibodies might be protective in mucosal transmission 
without being necessarily truly broad and potent as long as they are present in sufficient 
concentrations in the mucosa before viral transmission [187,236,254,255] The latter is 
based on the assumption that the virus is particularly sensitive to neutralization in the 
mucosa but also to antibody-based retention, antibody-dependent cellular cytotoxicity 
(ADCC) and other innate factors [187,236,255]. It has to be kept in mind however, that 
the RV144 trial was conducted with comparably low-risk volunteers and that the observed 
protection might be not representative for other parts of the world. Nevertheless, and 
while the induction of highly potent and very broad NAbs would undoubtedly be of huge 
advantage and should remain a goal, the need to induce truly broad and potent NAbs 
potentially sets the bar for recombinant gp140 too high given their superiority over the 
gp120 used in RV144 [244,245,256]. Additionally, the importance of protection at the 
mucosa gives additional momentum to studies addressing how to optimize mucosal 
Ig(immunoglobulin)G and IgA induction. Finally, additional clues for vaccine design are 
likely to come from the understanding of how to manipulate B-cell activation and affinity 
maturation in the course of vaccination[185]. 
 
In conclusion, the efforts underlying immunogen design demonstrated that the strategy to 
‘re-elicit’ [173] known broad NAb specificities is highly challenging and has largely failed 
so far. Nevertheless, the notable advances in immunogen design, the increasing 
description of vulnerable sites on Env, the improving understanding of mucosal 
transmission combined with the detailed characterization of the responses elicited in the 
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RV144 trial, increasing immunological understanding as well as the optimization of 
vaccination strategies offer hope and provide a number of specific paths forward. 
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2 AIMS	  OF	  THE	  THESIS	  
 
 
• To provide a detailed characterization of the molecular mechanisms underlying 
the enhanced immunogenicity observed upon introduction of p3P into Db-
restricted epitopes, including the generation of soluble TCRs for structural and 
biophysical analysis. 
 
• To achieve a structural understanding of the observed functional hierarchy of 
gp33 APLs and to apply the p3P modification on escape variants of the 
immunodominant LCMV epitope gp33. 
 
• To apply the p3P modification or the principles underlying its enhancement of 
immunogenicity to MHC-restricted TAAs. 
 
• To increase our molecular understanding of HIV neutralization and the interplay 
between the elicitation of neutralizing antibody responses and SIV evolution in 
vivo.  
 
• To test a novel vaccination strategy for its ability to induce potent neutralizing 
antibody responses against HIV. 
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3 RESULTS	  AND	  DISCUSSION	  
3.1 Enhancement	  of	  class	  I	  restricted	  viral	  and	  tumor-­‐associates	  epitopes	  	  
3.1.1 Recognition of gp33 variants by the P14 TCR 
LCMV infection elicits a potent immune response that is particularly directed against the 
immunodominant Db and H-2Kb (Kb) restricted epitope gp33 [257]. Crystal structure 
determination of gp33 in complex with Db revealed that the side chain of the tyrosine at 
position 4 of the peptide (Y4) protrude towards the TCR [258]. The highly efficient 
naturally occurring escape variant Y4F has been identified in mice that were transgenic for 
the murine Db/gp33-restricted TCR P14 [151]. Subsequently, Y4F as well as a number of 
designed APLs, including Y4A (KAVANFATM) and Y4S (KAVSNFATM), have been 
used extensively to characterize how peptide modifications affect CTL activation and 
TCR affinity [126,151,259,260] (Paper II Figure 1, Table 1). In summary, the results 
presented in Paper II, in agreement with previous studies have revealed the existence of 
an immunological hierarchy in which gp33 is a full agonist, Y4A a semi agonist and Y4F 
and Y4S are not recognized [151,259,261]. Furthermore, differences in the affinities of 
soluble P14 to the different Db/APL complexes followed a similar pattern [125,126,262].   
 
Surface stabilization assays and circular dichroism (CD) analysis confirmed that the 
observed functional differences could not be explained by the different MHC stabilization 
capacity of the APLs (Paper II Figure 2, Suppl. Figure 1). These results highlight the 
specificity of TCR binding and recognition described in the introduction where removal 
of a hydroxyl at the tip of Y4F is sufficient to abolish functional responses. Even more 
impressive is the fact that gp33 and Y4A display significant differences in immunogenicity 
in vitro while their binding by P14 differs only by 1 kcal/mol in free binding energy and/or 
roughly eight-fold in association rate. Although these values were not determined at 37°C 
they seem a fair approximation) (Paper II Table 1). Furthermore, the observed hierarchy 
of gp33 APLs is highly relevant with respect to the discussion regarding TCR specificity vs 
cross-reactivity given that P14 is able to at least partially recognize Y4A but neither Y4S 
nor Y4F. This means that P14 is able to partially tolerate the almost complete loss of the 
exposed side chain at position 4, whereas the relatively more conservative modification of 
Y4 of to a serine or a phenylalanine could not be tolerated (Paper II Figure 1a). While it 
seemed reasonable to assume that the hydroxyl group of tyrosine at position 4 rather than 
its aromatic ring is crucial for binding by P14, this would not explain why Y4A but not 
Y4S can compensate for the loss of this hydroxyl group.  
 
X-ray structure determination of the four different pMHCs did not reveal any 
conformational changes that could explain the observed differences in TCR recognition 
(Paper II Figure 4a, Suppl. Figure 3, Table 2). Nevertheless, inspection of the amount and 
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localization of the water molecules that surrounded the four peptide-binding clefts 
suggested a higher degree of coordination of waters only in the complex of Db/Y4S 
(Paper II Suppl. Figure 4) (see below). Furthermore, a thermodynamic analysis of the 
interactions of P14 with Db/gp33 and Db/Y4A revealed significantly distinct 
thermodynamic signatures (Paper II Figure 3; Table 1). While, binding of Db/Y4A by P14 
was associated with less favorable binding enthalpy, it did not result in the entropic 
penalty observed upon binding of P14 to Db/gp33. Instead, the P14 - Db/Y4A interaction 
derived its favorable free binding energy from a combination of both favorable binding 
enthalpy and binding entropy. 
 
Different thermodynamic strategies are not uncommon in TCR-pMHC interactions [263-
265], but it was nevertheless very interesting to observe that the small structural changes 
between Y4A and gp33 resulted in a reversal of the binding entropy despite being 
recognized by the same TCR. It could be possible that increased water expulsion from 
hydrophobic interactions and/or CDR rearrangements and flexibility drive the observed 
increase in binding entropy and association rate of the P14-Db/Y4A. One could further 
speculate that the increased water coordination in Db/Y4S when compared to Db/Y4A 
hinder this path of recognition by P14.  
 
In conclusion, this study highlights the yet highly unpredictable nature of the TCR-pMHC 
interaction with respect to even small changes in the presented peptides. Furthermore, it 
also emphasizes how the very small energetic and/or kinetic differences, that often 
characterize distinct TCR/pMHC interactions, make it entirely possible that the causative 
molecular changes are missed or simply not apparent in X-ray structures. 
3.1.2 Enhanced stability, immunogenicity and TCR-recognition of proline-substituted 
LCMV epitopes and a melanoma-associated TAA 
The p3P modification of Db-restricted epitopes described by van Stipdonk et al. [164] was 
both intriguing and promising for the design of APLs with enhanced stabilization capacity 
and immunogenicity. Position 3 has also been previously described as a secondary anchor 
residue for Db [266]. Furthermore, proline at this position had been noted as favorable but 
not enough to predict the striking increase in immunogenicity observed when EGS was 
modified to EGP. Targeting such minor anchor residues meant that the p3P modification 
could be applicable to a wide range of peptides that display poor immunogenicity despite 
containing favorable main anchor residues. Ultimately, the promise of the p3P 
modification was highlighted by the fact that it did not disturb the molecular mimicry 
between EGS and EGP as revealed by comparative structural analysis. Finally and most 
importantly, immunization of C57BL/6 mice with EGP cross-elicited CTL responses 
with sufficient avidity to lyse target cells that presented the native EGS epitope and thus 
delayed tumor growth [164].  
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The study presented in Manuscript III was based on these promising results and applied 
the p3P modification to possibly increase the immunogenicity of the LCMV peptides 
gp33, Y4A and Y4F. Furthermore, both studies summarized in Manuscript I and 
Manuscript III evaluated the direct impact of the p3P modification on TCR binding and 
pMHC stability. In each of the complexes tested, p3P increased the thermostability of the 
respective soluble pMHCs. However, the immunodominant gp33 as well as Y4F and Y4A 
displayed very strong binding to Db and the thermostability of the respective pMHCs was 
measured to around 53°C (Manuscript I Figure 1a) thus exceeding by far the 37°C 
measured for the TAA EGS (Manuscript III Figure 1, Table 1). In line with their already 
potent MHC stabilization capacity, the thermostability of the LCMV Db complexes was 
enhanced by only about 3-4°C upon p3P modification, while the thermostability of 
Db/EGS jumped to almost 50°C for Db/EGP in agreement with cellular stabilization 
assays [164]. 
 
SPR measurements with soluble recombinant P14 demonstrated that each of the p3P 
modified LCMV epitopes was recognized with small but significantly increased TCR 
affinity when presented by Db and compared to their native counterparts (Manuscript III 
Figure 1). The production, refolding and purification of a soluble recombinant form of 
Pmel, a murine TCR that recognizes Db/EGS, was established and the TCR used for SPR 
measurements comparing Db/EGS to Db/EGP (Manuscript I Figure 3a). These 
biophysical measurements confirmed that the p3P modification directly leads to a small 
but significant increase in TCR affinity. Furthermore, measuring the activation of P14+ 
CTLs with the enhanced epitopes PA (KAPANFATM) and PF (KAPFNFATM) 
demonstrated that the p3P modification resulted in significantly increased immunogenicity 
and converted the unrecognized Y4F into a semi-agonist (Manuscript III Figures 1+3, 
Suppl. Figures 2+3). Finally, vaccination of C57BL/6 with PF but not Y4F elicited a more 
focused CTL response against the native escape variant Y4F (Manuscript III Figure 4).  
 
In conclusion the results presented in Manuscripts I and III, combined with the 
previously published study [164], clearly demonstrated that p3P enhances MHC binding 
affinity, stabilization capacity, direct TCR affinity and overall immunogenicity of TAAs 
and immunodominant viral epitopes. p3P does not alter the conformation of the modified 
epitope, which leads to enhanced elicitation of CTL responses that cross-react with the 
native epitope.  
 
Additionally, the SPR measurements with the Db/EGS-specific Pmel TCR demonstrated 
that the native gp100 epitope EGS was recognized with an affinity generally characteristic 
for agonist epitopes, while it had been established that this peptide is not immunogenic in 
vivo [164,166]. This however, seems fitting with the hypothesis that promising TAAs are 
defined by the existence of cognate CTLs with sufficient avidity, which is made possible 
by their weak MHC stabilization capacity and limited negative selection [95-99].   
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On the other hand this summary does not address the molecular mechanism responsible 
for the increases in MHC stabilization capacity upon p3P modification. While the 
observation that the p3P modification results in direct increases of TCR affinity was 
interesting, it should be noted that they were generally small and that the strongly 
increased stabilization capacity observed for EGP could sufficiently explain its increased 
immunogenicity. Nevertheless, the fact that PF and PA also displayed enhanced 
immunogenicity in vitro when compared to their native counterparts supports the notion 
that the increases in TCR affinity are relevant given that the associated differences in 
MHC binding appear too small to have such an impact in these assays.  
3.1.3 Molecular basis underlying the enhanced MHC stabilization capacity and TCR 
recognition of Db/EGP 
Previous crystal structure analysis of Db/EGP indicated that the pyrrolidine ring of p3P 
closely interacted with the side chain of the MHC-I heavy chain tyrosine residue Y159, 
which is highly conserved among all known MHC alleles [164]. Accordingly, the authors 
proposed that specific interactions between proline and the aromatic ring of Y159 were 
responsible for the enhanced MHC binding and immunogenicity. Interactions between 
aliphatic CH donors, particularly prolines, and aromatic rings, so-called CH-π interactions, 
are commonly found in enzymatic systems and protein-protein interactions [267-275]. 
However, the role of this interaction has to date not been explicitly analyzed for peptide 
binding by MHCs. Additional analysis of crystal structures of Db/peptide complexes 
deposited in the Protein Data Bank (pdb, www.rcsb.org) revealed that the juxtaposition 
between Y159 and the side chain of position 3 (p3) of the bound peptides was highly 
conserved. These interactions were mediated in part by an absolutely conserved hydrogen 
bond interaction between the hydroxyl group of Y159 and the backbone carbonyl of 
peptide residue 1 [50] (Manuscript I Suppl. Figure 1). The conserved juxtaposition 
suggested that CH-π interactions at p3 may play an important and underappreciated role 
for the binding of Db restricted epitopes. 
 
The prominence of Y159 made it possible to use side-directed mutagenesis to address the 
contribution of the p3P-Y159 interaction to the enhanced Pmel affinity and stabilization 
capacity observed for EGP. Residue Y159 was mutated to phenylalanine (Y159F), leucine 
(Y159L) and to alanine (Y159A) in order to successively remove the chemical properties 
of Y159. Essentially, the measurements demonstrated that the striking difference in 
thermostability between Db/EGS and Db/EGP was entirely dependent on the aromatic 
rings of Y159 or F159 (Manuscript I Figure 1), as expected for CH-π interactions [271]. 
The data presented here therefore suggest that CH-π interactions between Y159 and p3P 
lead to enhanced MHC binding and stabilization capacity of Db-restricted epitopes.  
Furthermore, analysis of published epitopes eluted from Db+ cells demonstrated an 
overrepresentation of proline, as well as other aliphatic residues at position 3 that should 
be favorable for CH-π interactions [55,64,276]. However, to our knowledge, no 
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rationalization of such preferences has been published and it was interesting to note that 
while the prediction servers of the immunoepitope database (IEDB, 
http://www.immuneepitope.org) [277-280] and netMHC 
(http://www.cbs.dtu.dk/services/NetMHC/ [278]) did correctly predict higher binding 
affinity of EGP over EGS, proline was not listed as a favorable residue at position 3 in the 
binding motif of Db. In conclusion we therefore believe that the results of these studies 
combined with the published epitope elution and the conserved juxtaposition of p3 and 
Y159, indicate that CH-π interactions play an important role in shaping the amino acid 
preferences for position 3 of Db-restricted epitopes. Additionally, it should be noted that 
proline is described as main anchor at position 3 of H-2Dd epitopes [52,59,281], is 
observed in several Kb epitopes [55] and particularly in 9-mers as well as other 
unconventional Kb epitopes [5,282]. It is therefore tempting to speculate that these are 
aspects of the same mechanism, which is highly favorable for the binding of peptides 
containing p3P, while being constrained by the specific geometry of the MHC allele.  
 
Having established that the stability advantage conferred by EGP was lost in Db-Y159A 
made it possible to address if the differences in Pmel affinity were connected to the 
enhanced stabilization and dependent on interactions with Y159. Accordingly, the binding 
affinities of Pmel to Db-Y159F and Db-Y159A were determined in complex with EGS 
and EGP (Manuscript I Figure 3). Surprisingly, our results clearly demonstrated that the 
enhanced Pmel recognition of Db/EGP was conserved if not increased in Db-
Y159F/EGP and Db-Y159A/EGP. This clearly indicates that p3P leads to an increase in 
TCR recognition that is independent of direct interactions with the MHC peptide-binding 
cleft and therefore likely to be an effect that is mediated through the modified peptide.  
 
Subsequently, tetrameric complexes of Db/EGP, Db/EGS and Db-Y159F/EGP were 
generated and used to stain CD8+ Pmel T-cells (Manuscript I Figure 4). The use of pMHC 
tetramers at known concentrations made it possible to probe the functional significance of 
the small affinity differences observed in SPR, while avoiding the confounding effects 
from distinct MHC stabilization capacities and ensuing pMHC densities associated with 
cellular assays. In accordance with the SPR-measurements, a significant difference in 
staining intensity was observed between Db/EGP and Db/EGS. Furthermore, CD8+ 
Pmel T cells were stained with higher intensity by Db-Y159F/EGP tetramers compared to 
Db/EGS as expected from the thermostability and SPR measurements. Together with the 
increased immunogenicity observed for gp33-PF, whose stability advantage was too small 
to result in distinct cellular stabilization (data not shown), this suggests that the TCR 
affinity increases induced by p3P are correlated with functional differences in TCR 
recognition. 
 
Since the comparative analysis of the crystal structures of the various pMHCs provided no 
insights into the enhancement conferred by p3P [164], MD simulations were conducted to 
gain additional insights into differences between Db/EGP and Db/EGS. These results 
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(Manuscript I Figure 5) suggest that p3P stabilizes the Db/EGP complex by reducing the 
flexibility of the peptide-binding cleft, particularly at elevated temperatures (Manuscript 
III Figure 2). Additionally, the MD simulations indicated that the flexibility of the p3P-
modified EGP peptide was decreased when comparing Db/EGP and Db/EGS. While 
detailed analysis of the interactions between the peptide and the binding cleft as well as of 
TCR contact residues are still ongoing, these results are well in line with the striking 
differences in thermostability. Furthermore, other recent studies that investigated the 
influence of pMHC dynamics on TCR binding have suggested that increased pMHC and 
peptide flexibility is associated with decreased TCR affinity [113-115,283].  
 
In conclusion, the presented results demonstrate that interactions between Y159 and p3P 
are essential for the measured increase in MHC-I binding stability and point towards a 
fundamental role of CH-π interactions in Db-restriction. Nevertheless, p3P enhanced the 
TCR affinity of modified peptides independently of the p3P-Y159, suggesting a novel and 
unexpected role of p3P in the modulation of TCR recognition of Db-restricted epitopes.  
3.2 Elicitation	  and	  structural	  characterization	  of	  anti-­‐HIV	  antibodies	  	  
3.2.1 Crystal structure of the HIV-2 neutralizing anti-V3 Fab fragment 7C8 
Fab fragments of the murine monoclonal antibody 7C8 have been demonstrated to 
neutralize HIV-2 and bind to a stretch of V3-residues, which contain the highly conserved 
immunodominant motif FHSQ [284,285]. Papers IV and V summarize the crystallization 
and structure determination of the Fab fragment of 7C8 providing the first structural 
analysis of an HIV-2-neutralizing immunoglobulin. With the exception of the generally 
more variable CDRH3, all of the CDRs of 7C8 display one of the canonical classes 
defined for murine antibodies [286]. In line with most of the described potent anti-HIV 
antibodies, 7C8 features an elongated CDRH3 loop comprising 13 amino acid residues 
(Paper V Figure 1B). Fitting to its binding of the extended V3 region, the canonical classes 
found in 7C8 are most commonly observed in so-called peptide-binding antibodies and 
form, generally with shorter CDRH3 loops, a deep cleft that runs through the antigen-
binding site [287,288]. On the other hand, the elongated CDRH3 of 7C8 is localized at 
one end of its deep, narrow and highly hydrophobic cleft (Paper V Figure 2), similarly to 
the murine anti-HIV-1 V3 antibody 58.2 [289]. Although the need for these elongated 
CDRs in anti-HIV antibodies is still not entirely understood, it is likely related to the 
extensive shielding of epitopes on gp120 and might allow for more extensive contacts 
with the V3 epitope as exemplified in a number of human anti-V3 antibodies 
[218,290,291]. Finally, an analysis of the electrostatic surface potential of the Fab fragment 
of 7C8 demonstrated that the two sides of the deep antigen-binding cleft had distinct 
positive and negative surface charges (Paper V Figure 2), a property that is likely to play an 
important role in epitope binding and specificity.  
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A molecular model of the core domain of the HIV-2 gp125 (the homolog to HIV-1 
gp120) monomer, including the V3 region, was generated and a previously published 
analysis [194] used to create a putative disposition of the gp125 monomers in functional 
Env (Paper V Figure 3). Interestingly, and somewhat in contrast to previous comparisons 
[285], the sequence analysis clearly demonstrated that the conserved and 
immunodominant FHSQ motif does not align with the conserved and immunodominant 
GPGR motif found at tip of the V3 regions from HIV-1 clade B virus. Accordingly, the 
generated molecular model suggested that FHSQ is not localized at the tip but rather in 
the middle section of the V3 region (Paper V Figure 3). It should however, be noted that 
the precise conformation of the V3 region in the model remains speculative given its lack 
of secondary structure. The generated molecular models of gp125 were used to test if 
sensible binding modes could be established between the 7C8 Fab fragment and gp120 
using molecular docking simulations. Docking simulations are notoriously ambiguous 
especially if little experimental data is available to constrain them or validate their 
predictions [292,293]. These limitations prevented a reasonable detailed analysis of the 
interactions formed between V3 and 7C8 particularly as the two main solutions derived 
from the computational analysis displayed distinct orientations (Manuscript V Figure 4). 
However, all of the main docking solutions were highly focused on the FHSQ motif as 
expected from previous preliminary epitope characterizations [294] despite the fact that 
the docking procedure was not specifically directed towards this epitope (Manuscript V 
Figures 3). The two solutions could be superposed onto the trimeric model of g125 
(Manuscript V Figure 4) even if the size of potential glycans was taken into account (data 
not shown). The absence of sterical clashes together with the focus of 7C8 in the docking 
solutions on FHSQ provided at least an indirect validation of the obtained results and 
corresponded to the demonstrated immunodominance of this motif [284,285,295,296]. 
Finally, besides enforcing the importance of the FHSQ epitope for recognition by 7C8, 
the two models provide a potential mechanism for neutralization by 7C8, as the size of 
bound Fab fragments would sterically hinder subsequent engagement of the gp125 trimer 
with the co-receptor on the target cell.  
3.2.2 Induction of cross-reactive neutralizing antibodies in rabbits through a highly 
heterologous prime boost vaccination strategy 
As introduced above, our understanding of the binding sites of very broad NAbs has 
increased dramatically over the last years. Nevertheless, to date it has not been possible to 
fully translate this into the design of immunogens that elicit focused B-cell responses 
against these conserved and potentially vulnerable sites within Env. Therefore, a 
somewhat unusual approach was taken in Manuscript VI where a recombinant gp140 
trimer from SIVmac239 was used to boost antibody responses against HIV-1. The SIV boost 
followed repeating priming with a plasmid mix of three different clade B envs, which were 
injected intra-dermally together with adjuvant and electroporation. This strategy was based 
on the observation that recombinant trimers from SIV display increased stability during 
production, purification and storage when compared to their HIV-1 counterparts 
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(Manuscript VI Figure 1, GBSJ personal communication). While difficult to specifically 
address in vivo, this should be an important advantage for the induction of responses 
following injection. Additionally, the study was aimed at testing if the highly heterologous 
nature of the SIV boost with respect to the HIV prime would contribute to the elicitation 
of NAb responses particularly against the conserved and thus vulnerable epitopes. 
Although clade B HIV-1 and SIVmac239 Env share limited sequence conservation, certain 
important regions are conserved including the CD4bs (Manuscript VI Figure 1).  
 
Analysis of the resulting NAb responses indeed revealed high titer neutralization of clade 
B HIV-1 as well as persistent neutralization in sera collected up to three month after the 
last boost (Manuscript VI Figure 3). Importantly, significant levels of neutralization were 
also observed against viral isolates, which are less sensitive to neutralization (so called ‘Tier 
2’ isolates) as well as isolates of clades that were not represented in the HIV-1 DNA prime 
(Manuscript VI Figure 3F-I). A comparison of neutralization before and after the SIVmac239 
boost (week 16 and week 20, respectively) demonstrated that boosting increased NAb 
responses against most of the tested virus. Not surprisingly, no neutralization against 
HIV-1 was found in a control group that only received the recombinant SIV gp140 
trimer. Likewise, no neutralization of SIV was observed in serum collected prior to the 
SIV boost and the induced responses were not increased in primed animals (Manuscript 
VI Figure 3J, K).  In conclusion, this study clearly demonstrated that the vaccination 
strategy resulted in highly potent and notably broad NAb responses. Furthermore, the 
heterologous boost clearly increased the strength of the elicited antibody response 
including reactivity against heterologous virus. 
 
Epitope scanning for antibody binding responses revealed that the SIV boost primarily 
increased the responses that were already elicited by the prime (Manuscript VI Figure 4C). 
However, a site-wise analysis demonstrated that the level of responses prior to the boost 
did not necessarily determine the strength of the boost (Manuscript VI Figure 4A). For 
example responses against C1, C2 and V5 were most strongly increased. Interestingly, and 
in contrast to the observed neutralization, strong binding titers against SIV gp140 were 
detected already after HIV-1 priming and before the SIV protein boost (Manuscript VI 
Figure 2C).  
 
Using peptide-inhibition assays it was further demonstrated that a significant portion of 
the NAb responses was directed against the tip of the V3 region of gp120 (Manuscript VI 
Figure 5). Interestingly however, the neutralization inhibition by the V3 peptide was not 
complete, especially in some of the animals tested. Furthermore, a fraction of the 
neutralization responses could be inhibited with a heterologous V3 peptide from HIV-1 
clade A. Finally, further testing of peptide inhibition of neutralization and ELISA binding 
responses demonstrated that -as far as investigated- the observed parallel reactivity against 
HIV-1 and SIV was truly parallel and not due to antibody cross-reactivity (data not 
shown). In conclusion, the characterization of the antibody specificity demonstrated that a 
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significant fraction of the NAb response was directed against the immunodominant but 
escape-prone V3 regions, while lower levels of broad V3 neutralization responses as well 
as unrelated specificities were also observed.  
 
The influence of the adjuvants used during the prime was very limited and while some 
increase in antibody binding-titers were found (Manuscript VI Figures 2,4) no significant 
effect was observed in the neutralization assays. It should be noted that all neutralization 
assays were performed with specific target cells and are therefore insensitive to antibody 
effector functions such as ADCC.  
 
In summary these results demonstrate that the vaccination strategy led to the induction of 
NAb responses with considerable potency and breadth. The extent to which the observed 
effects were caused by the highly heterologous nature of the boost remains to be tested in 
detail. Nevertheless, this study clearly demonstrates that SIVmac239 gp140 trimers can be 
highly useful immunogens for the induction of NAbs against HIV-1. Accordingly, it 
seems appealing to identify the elements that confer higher stability to the SIV gp140 
trimer and transfer those to recombinant HIV trimers. This might lead to the creation of 
more potent HIV-1 based immunogens and would allow to individually test the 
contributions of gp140 trimer stability and heterologous nature for the capacity to boost 
NAb responses.  
3.3 Antibody	  responses	  and	  viral	  evolution	  in	  the	  host	  	  
3.3.1 Neutralizing antibody responses and evolution of SIV after early short-term 
antiretroviral therapy 
The study presented in Paper VII presents a comprehensive longitudinal analysis of the 
appearance of NAbs in the context of viral evolution in 12 experimentally-infected 
macaques that were subjected to early but short-term antiretroviral therapy (ART). During 
the course of 14 months the viral load, CD4+ T-cell counts, total antibody levels as well as 
the breadth and strength of NAb responses were measured. While early single drug 
treatment effectively controlled viremia in nearly all animals and while more than half of 
the animals demonstrated persistent control, another group only transiently controlled the 
infection and eventually developed high viremia and declining CD4 counts (Manuscript 
VII Figure 1, Table 1). Furthermore, these two groups were clearly segregated with 
respect to viral loads, NAb responses, Env diversity and divergence.  
 
Animals in which the virus eventually escaped control displayed greater env divergence and 
a larger number of positively-selected amino-acid substitutions including a number of 
well-characterized antibody escape mutations as well as mutations associated with 
increased replicative capacity (Manuscript VII Figures 2, 7, 8; Table 3; Suppl. Figure 3). 
The positively selected mutations within gp120 could be mapped to surface-exposed areas 
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and largely clustered in variable regions (Manuscript VII Figure 8; Suppl. Figure 5). 
Phylogenic analysis suggested that the increases in viral diversity and positively selected 
mutations occurred early and likely before differences in viremia became apparent 
(Manuscript VII Figures 2, 8; Suppl. Figures 3, 4). Not only did virus isolated from 
controlling macaques entirely lack notable escape mutations or mutations associated with 
increased replicative capacity, they also displayed less divergence and even signs of 
decreased neutralization resistance during the course of the study (Manuscript VII Figure 
5). Finally, it should be noted that a significant number of positively and negatively 
selected mutations in env have, at the time of the study, not been described in the 
literature, which highlights our limited understanding of SIV/HIV fitness and immune 
escape.  
 
Analysis of antibody responses in the different macaques demonstrated that animals 
controlling the infection displayed earlier signs of breadth in the neutralization response 
although they generally had markedly decreased NAb potency when compared to animals 
with higher viremia (Manuscript VII Figures 3, 5; Tables 2, 3). While this indicated that 
the potency of the NAb responses required a certain level of viremia and Env diversity, it 
is also tempting to speculate that early NAb breadth was responsible for the observed 
viral control. 
 
In conclusion, it was not possible to determine causalities in the interplay of ART, viral 
evolution and antibody responses. Nevertheless, this study allowed us to propose several 
hypothetical non-excluding scenarios, which could be specifically tested in subsequent 
experiments. Additionally, the different findings have important implications with respect 
to the application of post-exposure prophylaxis, therapeutic vaccination combined with 
treatment interruption and the elicitation of potent antibody responses: 
− The treatment could have played a crucial role in long-term control of virema by 
allowing the immune system to expand the HIV-specific CD4+ T cell repertoire 
without fueling infection.  
− Another crucial factor could have been the suppression of early increases in viral 
diversity (a hallmark of early HIV/SIV infection) as it might have allowed initial 
maturation of the adaptive immune responses without viral escape.  
− A number of crucial mutations might have, nevertheless, allowed the viral 
populations to increase in diversity eventually escaping immune control. This 
suggests a stochastic, somewhat ‘virus-centric’ process and could have re-established 
the ‘normal’ infection dynamic to the advantage of the virus. 
− A more ‘host-centric’ view could be proposed in which early development of NAbs 
of a certain breadth sufficiently crippled viral expansion during and after ART to 
allow long-term control of the infection. 
− Of importance for vaccination is that some NAb breadth was observed without high 
viral titers, while potent NAb responses were clearly correlated to high viremia. 
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However, it should be noted, that a large number of non-excluding factors that have not 
been addressed are probably also important and may thus play a crucial role. Those 
include CTL responses in combination with MHC polymorphisms and the possible 
appearance of drug resistance during ART. 
3.3.2 Properties of late-stage HIV-1 Env 
The results presented in Paper VIII are part of a series of studies that investigate how the 
characteristics of Env change in patients after the onset of AIDS [182,229,238,297]. This 
period is characterized by a significant depletion of the primary, CCR5-positive target cells 
as well as decreasing antibody immune pressure. Previous work demonstrated that late 
virus isolates were generally characterized by decreased CCR5 sensitivity, increased in vitro 
fitness, decreased DC-SIGN usage and increased surface charge. All together these studies 
suggested that changes in tropism and probably lower selection pressure from immune 
responses, resulted in significant changes to Env and viral fitness. Here, these 
characteristics were expanded by demonstrating that HIV-1 isolates, obtained after AIDS 
onset, were found to be more sensitive to neutralization by a commonly used mix of three 
broad NAbs (Paper VIII Figure 1). Furthermore, the increased neutralization sensitivity 
was correlated to increased replicative capacity and decreased CD4 counts (Paper VIII 
Table 2). Analysis of env revealed that the late-stage Env displayed reduced numbers of 
predicted glycosylation sites, which were localized in proximity to the 2G12 glycan epitope 
(Paper VIII Figures 4, 6; Table 2).  
 
In conclusion, this study demonstrates that the transition to late-stage disease is 
accompanied by significant changes in Env, which seem to arise in an opportunistic 
manner as the immune response begins to collapse break down and allow the virus to 
maximize replicative capacity over neutralization resistance. The observed decrease in 
glycosylation sites during the late-stage of the disease is well in line with results from 
studies that have strongly linked glycosylation to neutralization resistance and specifically 
demonstrated glycosylation to increase during the early phase of infection 
[181,229,231,233] as well as during the epidemic [176]. The changes highlight the extreme 
variability and plasticity of the viral fusion machinery and to some extent mirror the 
changes in Env observed in laboratory-isolates. However, significant changes might also 
be forced upon Env as the primary CCR5+ CD4+ T-cell population is increasingly 
depleted.  
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FUTURE	  DIRECTIONS	  
The following section will suggest one or two key experiments or directions that could be 
taken to expand the findings for each of the projects comprised in this thesis. 
 
Manuscript I: Molecular basis underlying enhanced immunogenicity of optimized 
H-2Db-restricted melanoma-associated epitopes 
− Thermodynamic measurements of pMHC dissociation and TCR binding with the 
pMHC complexes used in this study to provide a more complete basis for the 
understanding of how p3P enhances TCR binding. 
− Transfection of Db-negative APCs with constructs expressing the different Db-
mutants in order to further dissect the relative contributions of increased stabilization 
capacity and increased TCR binding to the enhanced immunogenicity of EGP in vivo.  
 
Paper II: The unexpected T-cell recognition of an altered peptide ligand is 
driven by reversed thermodynamics 
− Crystal structure determination of P14 in complexes with Db/gp33 and Db/Y4A 
complemented by thermodynamic measurements with P14-Db/Y4S that aim at 
modifying water coordination. 
 
Manuscript III: Induction of efficient CTL responses against a viral escape mutant 
through an unconventional peptide optimization 
− Using LCMV infections of C57BL/6 and P14 transgenic mice to establish the effect 
of prophylactic and therapeutic vaccination with PF. 
− Determination of the crystal structures of P14 in complex with Db/gp33 and Db/V3P. 
  
Papers IV, V: Crystal structure of the HIV-2 neutralizing Fab fragment 7C8 with 
high specificity to the V3 region of gp125 
− Crystal structure determination of HIV-2 gp125 alone and in complex with 
neutralizing Fab fragments. 
 
Manuscript VI: SIVmac239 gp140 trimers induce potent cross-reactive HIV-1 
neutralization when primed with HIV-1 Envelope DNA mixture 
− Attempts to more extensively characterize the specificities of the elicited neutralisation 
response, potentially through the use of specific antibody-depletion steps. 
− Extensive comparisons of how modifications to the HIV DNA prime or SIV protein 
boost affect the elicited neutralization response including a direct comparison of SIV 
and HIV protein boost. 
 
Manuscript VII: Generation of neutralizing antibodies and divergence of 
SIVmac239 in cynomolgus macaques following short-term early antiretroviral 
therapy 
 
 
 
37 
 
 
 
− Testing if the occurrence of mutations that confer resistance to ART could have 
affected the ability of the virus to expand its diversity and escape immunological 
control. 
− Beginning to address the contributions of CTL pressure and escape on the 
outcome of this study. 
 
Manuscript VIII: Increased sensitivity to broadly neutralizing antibodies of end-
stage disease R5 HIV-1 correlates with evolution in Env glycosylation and charge 
− Parallel analysis of neutralization responses, CD4+ T-cell repertoire and preferred 
target cells to establish if changes in neutralization pressure or tropism primarily 
drive the in the changes observed in Env.  
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